{"abstract":"This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to practice the inventions embodied in the following patent applications to Chimeron Bio Corporation, a company incorporated under the laws of Delaware and having an office in Philadelphia, PA. Intellectual Property: U.S. Provisional Patent Application No.: 61/ 615,687 Entitled \"Delivery of Packaged RNA in Mammalian Cells\" HHS Ref. No.: E-264-2011/0-US-01 Filed March 26, 2012; International Patent Application No.: PCT/US2013/031876 Entitled \"Delivery of Packaged RNA in Mammalian Cells\" HHS Ref. No.: E-264-2011/0-PCT-02 Filed March 15, 2013; Australian Patent Application No.: 2013-240248 Entitled \"Delivery of Packaged RNA in Mammalian Cells\" HHS Ref. No.: E-264- 2011/0-AU-03 Filed October 17, 2014; European Patent Application No.: 13712661.1 Entitled \"Delivery of Packaged RNA in Mammalian Cells\" HHS Ref. No.: E-264-2011/0-EP-04 Filed October 24, 2014; Japanese Patent Application No.: 2015-503322 entitled \"Delivery of Packaged RNA in Mammalian Cells\" HHS Ref. No.: E-264-2011/0-JP-05 Filed September 25, 2014; U.S. Patent Application No.: 14/388,441 Entitled Delivery of Packaged RNA in Mammalian Cells\" HHS Ref. No.: E-264-2011/0-US-06 Filed September 26, 2014; U.S. Provisional Patent Application No.: 61/ 916,394 Entitled \"Cancer Immunotherapy: Delivery HLA-11 using VLP- Replicon\" HHS Ref. No.: E-050-2014/0-US-01 Filed December 16, 2013; International Patent Application No.: PCT/US2014/070552 Entitled \"Cancer Immunotherapy: Delivery HLA-11 using VLP-Replicon\" HHS Ref. No.: E-050-2014/0-PCT-02 Filed December 16, 2014; The patent rights to these inventions have been assigned to the Government of the United States of America. The prospective exclusive start-up licensed territory may be worldwide and the field of use may be limited to: \"Use of virus like particles comprising MHCII and CD80 for the treatment of breast cancer, lung cancer, melanoma, pancreatic cancer, and hepatocellular cancer.\"","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/05/18/2016-11661.html","cfr_references":[],"citation":"81 FR 31250","comment_url":null,"comments_close_on":"2016-06-02","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before June 2, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-11661","effective_on":null,"end_page":31251,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/05/18/2016-11661.xml","html_url":"https://www.federalregister.gov/documents/2016/05/18/2016-11661/prospective-grant-of-start-up-exclusive-license-development-of-virus-like-particles-for-the","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-11661?publication_date=2016-05-18","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-05-18/2016-11661/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":367,"last_updated":"2026-08-25 02:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-05-18/pdf/2016-11661.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-11661.pdf?1463489151","publication_date":"2016-05-18","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/05/18/2016-11661.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T07:44:55Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":31250,"subtype":null,"title":"Prospective Grant of Start-up Exclusive License: Development of Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, and Hepatocellular Cancer","toc_doc":"Development of Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, and Hepatocellular Cancer","toc_subject":"Start-up Exclusive License Approvals:","topics":[],"type":"Notice","volume":81}